Phibro Animal Health (PAHC) investor relations material

Financial performance and recent results

• Achieved 21% revenue growth and 60% adjusted net income growth in the recent quarter, driven by strong integration of the Zoetis Medicated Feed Additive (MFA) portfolio and robust performance in vaccines and nutritional specialties.

• Legacy MFA business saw a temporary 5% decline due to order timing, but underlying growth remains positive with expectations for recovery in the second half of the year.

• Raised guidance for revenue, EBITDA, and adjusted net income based on strong first-half results and positive investor feedback.

Strategic direction and business mix

• The acquired Zoetis MFA portfolio is expected to be fully integrated by fiscal 2027, with MFAs becoming a larger share of the business.

• Vaccines and nutritional specialties are targeted for mid to high single-digit growth, supported by R&D investment and geographic expansion.

• Companion animal business is a long-term focus, with new products launched and a strategy to reinvest profits for future growth.

Market dynamics and growth drivers

• Growth attributed to robust animal protein consumption, demographic trends, and increased demand for meat and dairy despite inflation.

• Innovation, new product launches, and geographic expansion in MFAs, vaccines, and nutritional specialties have contributed to market share gains.

• The company is well-diversified across livestock markets, mitigating risks from cyclical or regional shifts.